For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. |
Managed Health Care Q3 2026 Earnings & Post-Midterm PolicyDefinitionTracks the U.S. managed health care sub-industry (Health Care sector): the Q3 2026 earnings read-through on medical cost trends and the policy agenda after the Democratic sweep of Congress in the November 2026 midterms (CFRA, Daniel Rich, 11/11/2026). Investment thesis
Policy map (divided government: Democratic Congress, Trump veto)
CFRA 12-month targets and 2027E multiples (11/11/2026)
RisksCost reacceleration (utilization, GLP-1, specialty drugs, respiratory season), PBM legislation and oversight, insufficient federal/state reimbursement, provider consolidation, actuarial mispricing. Coverage gapsDedicated pages now exist for CVS Health Corporation and Elevance Health, Inc.. Humana, Centene and Molina are pending (raw stock reports dated 11/11/2026 await ingest); they are named here without links until written. RelatedExposed companies (7) The Cigna GroupCI US CVS Health CorporationCVS US Centene CorporationCNC US Humana Inc.HUM US UnitedHealth Group IncorporatedUNH US Elevance Health, Inc.ELV US Molina Healthcare, Inc.MOH US |
Research Theme
Managed Health Care Q3 2026 Earnings & Post-Midterm Policy
Exposed Universe7 Companies
Last Updated2026-11-11
Loading graph…
Definition
Tracks the U.S. managed health care sub-industry (Health Care sector): the Q3 2026 earnings read-through on medical cost trends and the policy agenda after the Democratic sweep of Congress in the November 2026 midterms (CFRA, Daniel Rich, 11/11/2026).
Investment thesis
- Margins over membership: all 7 CFRA-covered insurers (CVS, CNC, ELV, HUM, MOH, CI, UNH) beat Q3 consensus and 6 raised 2026 guidance, via market exits, large premium increases and AI-assisted cost control.
- Cost trend: stabilizing, not normal: medical cost ratios rose sequentially through 2026 and stay above historical levels, but fell Y/Y for CVS, ELV, UNH (CNC flat). HUM is the outlier (+260 bp Y/Y, still better than guided). Medicaid margins look to be troughing in 2026 (MOH, ELV, UNH); MA improvement owes more to repricing than to cost deceleration.
- Humana read-through: 2027 MA Stars show 95% of members in 4.0+ star plans (20% for 2026), a potential tailwind; but core MA cost trend is seen accelerating to 8-9% in 2027 on Part D drugs.
- CVS breakup (11/04/2026): retail pharmacy (CVS Pharmacy) to separate from Caremark, Aetna, Oak Street and Signify (CVS Health) by 1H 2028, tax-free. CFRA reads it as a response to regulatory pressure on vertical integration. Washington Analysis sees low risk of a similar split at UNH or CI (no retail chain), but more PBM scrutiny.
Policy map (divided government: Democratic Congress, Trump veto)
- No Surprises Act / IDR reform: 35% odds of targeted reform; bipartisan (Guthrie / Pallone). UNH, ELV, CI, CVS are beneficiaries, UNH the most (IDR commercial cost trend +11% Y/Y; about 100 bp of total medical costs cited in Q2).
- OBBBA: Medicaid work requirements and redeterminations (1 Jan 2027) very likely proceed, a headwind for CNC, MOH, ELV, UNH. 40% odds that later provisions (state-directed payments, provider taxes, toward 2028) are delayed, a positive for CNC, MOH, UNH, ELV.
- ACA enhanced premium tax credits: expired end-2025; 35% odds of restoration in a year-end funding deal. Positive for ELV, CNC, MOH; CVS (Aetna) already out, CI exiting by year-end, MOH shrinking exposure.
CFRA 12-month targets and 2027E multiples (11/11/2026)
- UNH: $450, 19.3x 2027E EPS (premium to peers).
- ELV: $500, 16.7x. CNC: $79, 13.9x. CVS: $95, 10.7x. CI: $345, 10.3x. All on 2027E EPS.
- HUM: $465, 27.2x 2027E EPS on depressed earnings (2026 is the lowest adjusted EPS since 2015).
- MOH: $235, 24.2x forward P/E and 11.4x 2027E EV/EBITDA (normalized 7-8x); not directly comparable with the P/E-only names without using the P/E figure.
Risks
Cost reacceleration (utilization, GLP-1, specialty drugs, respiratory season), PBM legislation and oversight, insufficient federal/state reimbursement, provider consolidation, actuarial mispricing.
Coverage gaps
Dedicated pages now exist for CVS Health Corporation and Elevance Health, Inc.. Humana, Centene and Molina are pending (raw stock reports dated 11/11/2026 await ingest); they are named here without links until written.






